Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.24% | -17.70% | -12.53% | -13.13% | -30.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.24% | -17.70% | -12.53% | -13.13% | -30.88% |
| Cost of Revenue | 0.89% | -35.18% | 333.37% | 242.28% | 203.86% |
| Gross Profit | -1.66% | -13.26% | -30.16% | -24.91% | -39.98% |
| SG&A Expenses | 6.19% | 6.30% | -0.38% | -11.75% | -15.51% |
| Depreciation & Amortization | -25.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.14% | -13.81% | -5.74% | -19.85% | -18.65% |
| Operating Income | 46.98% | -3.30% | -58.42% | 43.15% | -15,227.35% |
| Income Before Tax | -5.30% | -33.68% | 21.53% | 58.82% | 25.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.30% | -33.68% | 21.53% | 58.82% | 25.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.30% | -33.68% | 21.53% | 58.82% | 25.28% |
| EBIT | 46.98% | -3.30% | -58.42% | 43.15% | -15,227.35% |
| EBITDA | 150.84% | -24.20% | -70.74% | 123.06% | -88.52% |
| EPS Basic | 3.07% | -17.67% | 29.95% | 61.99% | 29.14% |
| Normalized Basic EPS | 4.71% | -14.43% | -49.02% | 46.58% | -277.22% |
| EPS Diluted | 4.03% | -18.46% | 30.25% | 61.90% | 31.69% |
| Normalized Diluted EPS | 4.31% | -14.43% | -49.02% | 46.58% | -226.09% |
| Average Basic Shares Outstanding | 13.54% | 12.52% | 9.55% | 7.22% | 4.58% |
| Average Diluted Shares Outstanding | 14.25% | 12.44% | 9.63% | 7.30% | 3.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |